Septerna, Inc. (NASDAQ:SEPN - Get Free Report) insider Samira Shaikhly sold 70,453 shares of the firm's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $28.10, for a total value of $1,979,729.30. Following the transaction, the insider owned 793 shares in the company, valued at $22,283.30. This represents a 98.89% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Septerna Trading Up 2.5%
Shares of NASDAQ SEPN opened at $28.83 on Thursday. The stock has a market cap of $1.29 billion, a P/E ratio of -19.09 and a beta of 3.46. Septerna, Inc. has a twelve month low of $4.66 and a twelve month high of $32.63. The stock has a 50 day moving average of $26.91 and a two-hundred day moving average of $22.70.
Institutional Investors Weigh In On Septerna
Hedge funds and other institutional investors have recently modified their holdings of the stock. Group One Trading LLC boosted its stake in shares of Septerna by 111.8% during the 4th quarter. Group One Trading LLC now owns 944 shares of the company's stock worth $26,000 after acquiring an additional 8,955 shares in the last quarter. Global Retirement Partners LLC acquired a new position in Septerna during the fourth quarter worth $35,000. Russell Investments Group Ltd. acquired a new position in Septerna during the third quarter worth $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in Septerna during the fourth quarter worth $53,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Septerna in the fourth quarter valued at $61,000.
Analyst Upgrades and Downgrades
A number of research analysts have commented on SEPN shares. Truist Financial started coverage on shares of Septerna in a research note on Monday, December 15th. They issued a "buy" rating and a $34.00 price objective on the stock. HC Wainwright raised their price target on Septerna from $35.00 to $40.00 and gave the stock a "buy" rating in a report on Monday. Raymond James Financial began coverage on Septerna in a research note on Friday, December 19th. They set a "strong-buy" rating and a $38.00 price objective for the company. Wall Street Zen downgraded Septerna from a "strong-buy" rating to a "buy" rating in a research note on Saturday, January 10th. Finally, Wells Fargo & Company boosted their target price on Septerna from $28.00 to $48.00 and gave the company an "overweight" rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Septerna has an average rating of "Moderate Buy" and a consensus price target of $38.00.
Get Our Latest Stock Analysis on Septerna
Septerna Company Profile
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
